Research Article

Quality by Design (QbD) Approach for Enhancement–the Dissolution Rate of Lafutidine Liquisolid Tablets

Tushar Gohil1*, Nishant Oza2, Hitesh Vekariya3

1Department of Pharmaceutics, Smt. C. V. Gajera Pharmacy Mahila College, Amreli-65601, Gujarat, India
2C. U. Shah College of Pharmacy and Research, Wadhwan City 363030, Gujarat, India
3R. K. University, Rajkot-360001, Gujarat, India

ABSTRACT

The aim of present work was to enhancing the solubility and dissolution rate of the aquaphobic drug lafutidine by liquisolid technique. Lafutidine is an H2-receptor antagonist BCS class II drug. Lafutidine compatibility with excipients was evaluated by Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) spectrum. Preliminary trial taken to check the effect of carrier to coating material ratio (R) and non-volatile solvent (PEG-600) on pre- and post-compression characteristic. Flowable liquid retention potential (φ-value) and liquid load factors (Lf) were calculated for required amount of excipients necessary to preparing lafutidine liquisolid tablet. A 32 full factorial design was employed to check the effect of carrier to coating material ratio R (X1) and PEG-600 (X2) on hardness (Y1), angle of repose (Y2), % of cumulative drug release at 5 minutes Q5 (Y3), and disintegration time (Y4). Multiple linear regression analysis, ANOVA, and graphical representation of the influence of factor by 3D plots were performing by using Design Expert 7.0. In this study, the following constraints were arbitrarily used for the selection of an optimized batch: hardness: 3 to 5.5, angle of repose: 25 to 30, % of cumulative drug release at 5 minutes Q5 > 27.09%, and disintegration time < 1.3 minutes. The desirability value of various dependent variables calculated for determining the optimized batch of tablet and it was also found to be nearer to one. Performance of optimized batch had no shown any significant change at the end of stability study.

INTRODUCTION

The BCS class II drugs have poor solubility and less dissolution rate in the fluid present at the absorption site. Therefore, BCS class II drugs were shown very poor bioavailability. Their bioavailability can improve by increasing the solubility and enhancement of the dissolution rate. In the last few years, so many novel techniques such as micronization, solid dispersion, inclusion complex, lyophilization, microencapsulation, and liquisolid tablets were developed to enhance the dissolution rate of aquaphobic drug. However, among them the “liquisolid tablets” is one of the most promising techniques to improve the solubility and dissolution rate.1-3 In liquisolid technology, the aquaphobic molecules are solubilized in a water-miscible non-volatile solvent and liquid transformed into a free-flowing, readily compressible dry powder by simple physical blending with the carrier and coating material. Liquisolid technique also improved the drug wetting property of aquaphobic drugs. Therefore, the drug dissolution profile is also improved. In addition, this technique has uncomplicated and low-cost production.4 Lafutidine belongs to BCS class II drug. It is an anti ulcerative agent indicated for the treatment of ulcers, and it suppresses gastric acid secretion. Lafutidine is practically poorly soluble in water. Thus, it has less than 15% bioavailability.5,6 Hence, the aim of the present study is made to formulate the lafutidine 10 mg liquisolid tablets by using 32 full factorial designs, which will improve the solubility and dissolution rate of lafutidine. In this study, the following constraints were arbitrarily used for the selection of an optimized batch: hardness: 3 to 5.5, angle of

*Corresponding Author: Dr. Tushar A. Gohil
Address: Department of Pharmaceutics, Smt. C. V. Gajera Pharmacy Mahila College, Amreli-65601, Gujarat, India
Email: gohil1313@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Tushar Gohil et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
repose: 25 to 30%, of cumulative drug release at 5 minutes (Qₚ) > 27.09%, and disintegration time < 1.3 minutes.

**Materials and Methods**

**Materials**

Lafutidine was gifted by Emcure Pharma Ltd., Mumbai. Propylene glycol, tween-80, span-80, glycerin, peg-200, peg-400, peg-600, sodium starch glycolate (SSG), polyvinyl pyrolidone K-30 (PVP K-30), and magnesium stearate were obtained from Loba Chemicals Pvt. Ltd., Mumbai, India. Avicel PH-101, avicel PH-102, aerosil, and cab-o-sil were obtained from Chemdyes Corporation, Rajkot, India. All other materials and chemicals used were of either pharmaceutical or analytical grade.

**Characterization and Drug-Excipients Compatibility Study**

The maximum wavelength (λ_{max}) determination of the drug was done using a UV spectrophotometer (Jasco V-550, Japan). Drug excipient interaction plays a vital role in achieving stability of drug in dosage form. FTIR was used to study the physical and chemical interactions between drugs and excipients. FTIR spectra of lafutidine and formulation were obtained by using the FTIR instrument (JASCO-460 Plus, Japan). DSC thermograms of lafutidine and formulations were obtained by using an automatic thermal analyzer system (Mettler Toledo DSC 821e, Mumbai, India). The analysis was performed at a rate of 20°C/min from 50 to 300°C under a nitrogen flow of 20 mL/min.

**Preliminary Screening of Non-Volatile Solvents, Carrier Materials, and Coating Materials**

**Selection of Non-Volatile Solvent**

Non-volatile solvent was selected based on the solubility study. The solubility of lafutidine in various non-volatile solvents, such as, propylene glycol, PEG 200, PEG 400, PEG 600, span 80, tween 80, and glycerin was determined by saturated solubility method. In this method, excess amount of lafutidine was added in a 2 mL of each vehicle, and this solution was shaken on an isothermal mechanical shaker at 37 ± 0.5°C for 48 hours. Supernatants were filter, weigh, and diluted with 0.1 N HCl. The drug content was analyzed by spectrophotometrically at 286 nm.

**Selection of Carrier and Coating Material**

Carrier and coating material were selected based on flowable liquid retention potential (Φ value) and liquid load factors (Lq). In preliminary screening, avicel PH 101, avicel PH 102, and lactose were taken as carrier material. In preliminary trials, aerosil, aerosil 200, and cab-o-sil were taken as a coating material. The liquid retention potential (Φ value) of a powder is the maximum amount of given non-volatile liquid that can be retained inside powder bulk (w/w) while maintaining acceptable flowability. In this study, 4 grams of coating or carrier material was mixed with increasing amount of non-volatile solvent using a mortar and pestle. Then each mixture was placed on a metal plate and at each addition angle of repose was determined. The flowable liquid-retention potential (Φ value) of each mixture was calculated using the following equation.

\[ \Phi = \text{Weight of liquid/Weight of solid} \]

Each mixture has specific Φ value, which were determined and plotted against respective measured angle of slide for all non-volatile liquid vehicles. The Φ value that corresponds to an angle of slide of 33°, was reported to represent the flowable liquid retention potentials of powder mixtures. Whereas, liquid load factors (Lq) is the mass ratio (w/w) of the liquid medication to the carrier powder in the liquisolid formulation.

**Preliminary Trial Batches of Lafutidine 10 mg Liquisolid Tablets**

Preliminary trial of lafutidine 10 mg liquisolid tablets was taken to check the effect of carrier to coating material ratio (R) and non-volatile solvent (PEG-600) on pre- and post-compression characteristic. Preliminary trial batches formulation of lafutidine liquisolid tablets is shown in Table 1. Trial batch of Liquisolid tablets were prepared by using PEG600 as a non-volatile solvent, avicel PH 101 as carrier material, and aerosil-200 as coating material. In this formulation, Q = W/Lq and q = Q/R. Batch T1 to T5 was canting 5 to 25 carrier to coating material ratio (R) and non-volatile solvent (PEG-600).

**Table 1: Formulation of preliminary trial batches**

| Batch | Lafutidine (mg) | PEG-600 (mg) | Total wt. of liquid (W) (mg) | Ratio of carrier to coating (R) | Liquid load factor (Lq) | Avicel PH 101 (mg) (Q) | Aerosil-200 (mg) | Wt. of tablets (mg) |
|-------|----------------|--------------|-----------------------------|-------------------------------|------------------------|-----------------------|----------------|-------------------|
| T1    | 10             | 11.69        | 21.69                       | 5                             | 0.3227                  | 67.21                 | 13.44          | 113.6             |
| T2    | 10             | 23.37        | 33.37                       | 10                            | 0.2552                  | 130.76                | 13.07          | 196.71            |
| T3    | 10             | 35.06        | 45.06                       | 15                            | 0.2326                  | 193.72                | 12.9           | 279.37            |
| T4    | 10             | 46.74        | 56.74                       | 20                            | 0.2214                  | 256.28                | 12.81          | 361.67            |
| T5    | 10             | 58.43        | 68.43                       | 25                            | 0.2146                  | 318.87                | 12.75          | 444.05            |
### Full Factorial Design for Development of Lafutidine 10 mg Liquisolid Tablets

Full factorial batches formulation are of lafutidine liquisolid tablets are shown in Table 2. In this, batch 10 mg lafutidine was dissolved in polyethylene glycol 600, which was used as a non-volatile solvent. The drug solution was added to avicel PH 101 (carrier material) and mixed properly in mortar and pestle. This mixture was allowed to stand for 10 minutes then add aerosil-200 as a coating material to obtain free-flowing powder. Finally, 5% of sodium starch glycolate (disintegrant), 5% polyvinyl pyrrolidone k 30 (binder), and 1% magnesium stearate (lubricant) was added to the above mixture and mixed thoroughly. The final mixture was compressed into tablets by using rotary tablet machine, and liquisolid tablets were evaluated for pre- and post-compression characteristics.\(^{[13]}\)

A $3^2$ randomized full factorial design was used in the present study. In this design, two independent factors were evaluated, each at three levels, and experimental trials were performed for all nine possible combinations. The carrier to coating material ratio ($X_1$) and polyethylene glycol 600 ($X_2$) was chosen as independent variables in $3^2$ full factorial design, while hardness ($Y_1$), angle of repose ($Y_2$), % of cumulative drug release at 5 minutes ($Y_3$), and disintegration time ($Y_4$) were taken as dependent variables. Multiple linear regression analysis, ANOVA, and graphical representation of the influence of factor by contour plots were performed using Design Expert 7.\(^{[13,14]}\)

The experimental runs and measured responses of $3^2$ full factorial design batches of lafutidine liquisolid tablets were depicted in Table 4. The desirability function approach is one of the most widely used methods for the optimization of multiple response processes. The desirability function combines all the responses into one variable to predict the optimum levels for the independent variables. A desirability value of 0 represents an unacceptable value for the responses, and a value of 1 represents the most desired value for the responses.\(^{[14]}\)

### Evaluation of Lafutidine Liquisolid Tablets

Pre-compression and solid dispersions were evaluated for bulk density, tapped density, Hausner ratio, Carr’s compressibility index, and angle of repose as described by Khalid E et al. and Boghra R et al. Post compression parameters, like weight variation, thicknesses, hardness, friability, content uniformity, and disintegration time studies were performed, as described by Babatunde A et al., Javadzadeh Y et. al., and Spiro S et al.\(^{[15-19]}\)

### In vitro Drug Release Study

This study was carried out by using a United States Pharmacopeia (USP) type-II dissolution test apparatus (apparatus 2, 100 rpm, 37 ± 0.5°C) in stimulated gastric fluid without enzyme-containing 0.1 N HCl. Aliquots of 10 mL were withdrawn at different time interval. Solution filtered through 0.45 µm filter paper and the content of lafutidine was analyzed using UV spectrophotometer at 286 nm.\(^{[20,21]}\)

### Stability Studies

According to ICH guideline stability studies of optimized formulation was determined by using stability chamber (make: Remi Equipments Ltd., Mumbai, model-CHM-6S), and the samples placed in screw-capped vials under ambient conditions at 40°C and 75% RH for 3 months. The selected formulation was evaluated for their hardness, friability, disintegration time, in vitro drug release, and drug content. The similarity factor ($f_2$) was used to evaluate the drug release.

$$f_2 = \Phi \log \left[ 1 + \frac{1}{n} \sum_{t=1}^{n} (R_t - T_t)^2 \right]^{0.5} \times 100$$

Where log is logarithm to the base 10, $n$ is the number of time points, $\sum$ is summation over all time points, $R_t$ is

### Table 2: Formulation of $3^2$ full factorial design batches of lafutidine 10 mg liquisolid tablets

| Batch | Lafutidine (mg) | PEG-600 (mg) | Total wt. of liquid (W) (mg) | Ratio of carrier to coating (R) | Liquid load factor ($L_d$) (mg) | Avicel PH 101 (mg) (Q) | Aerosil-200 (mg) (q) | Wt. of tablets (mg) |
|-------|----------------|--------------|-----------------------------|--------------------------------|-------------------------------|-----------------------|---------------------|------------------|
| F₁    | 10             | 35.06        | 5                           | 45.06                          | 0.3227                        | 139.63                | 27.92               | 235.99           |
| F₂    | 10             | 35.06        | 12.5                        | 45.06                          | 0.2416                        | 186.5                 | 14.92               | 273.58           |
| F₃    | 10             | 35.06        | 20                          | 45.06                          | 0.2213                        | 203.61                | 10.18               | 287.33           |
| F₄    | 10             | 58.43        | 5                           | 68.43                          | 0.3227                        | 212.05                | 42.41               | 358.39           |
| F₅    | 10             | 58.43        | 12.5                        | 68.43                          | 0.2416                        | 283.23                | 22.65               | 415.47           |
| F₆    | 10             | 58.43        | 20                          | 68.43                          | 0.2213                        | 309.21                | 15.46               | 436.33           |
| F₇    | 10             | 81.8         | 5                           | 91.8                           | 0.3227                        | 284.47                | 58.89               | 480.79           |
| F₈    | 10             | 81.8         | 12.5                        | 91.8                           | 0.2416                        | 379.96                | 30.39               | 557.37           |
| F₉    | 10             | 81.8         | 20                          | 91.8                           | 0.2213                        | 414.82                | 20.74               | 585.55           |

All the formulations contain 5% SSG, 5% PVP K-30, and 1% MG stearate.

---

*Int. J. Pharm. Sci. Drug Res. May-June, 2020, Vol 12, Issue 3, 238-246*
the mean dissolution value of the reference profile at time \( t \), and \( T \) is the mean dissolution value of the test profile at the same time point. The USFDA draft guidance document contains more information on similarity factor (\( f_2 \)). The value of similarity factor (\( f_2 \)) between 50 and 100 suggests that the two dissolution profiles are similar.\(^{[22]}\)

**RESULTS AND DISCUSSION**

**Characterization and Drug-Excipients Compatibility Study**

Lafutidine maximum absorbance was found to be at 286 nm in 0.1 N HCl. Compatibility study of lafutidine was carried out to determine the drug-excipients interaction. FTIR spectra of lafutidine and formulation were recorded using KBr mixing method on FTIR instrument. The FTIR spectra of pure drug and formulation are shown in Figs 1A and B. Lafutidine exhibited peaks due to C=O, C-H, –CH\(_2\), S=O, and C-S stretching. It was observed that there were no or very minor changes in drug main peaks in the IR spectra of the drug and formulation. The FTIR study revealed no physical or chemical interaction of drug with excipient. The DSC thermograms of lafutidine showed in Fig. 1C, sharp endothermic peak at 104.22°C, indicating that the drug is highly crystalline. The absence of drug peak in the thermograms of formulation (Fig. 1C) indicated the drug was converted into an amorphous form. The intensity of the endotherm was markedly decreased in the liquisolid formulation. It was shown that reduction in the crystallinity of the drug give faster drug release from the formulation.

**Preliminary Screening of Non-Volatile Solvents, Carrier Materials, and Coating Materials**

**Selection of Non-Volatile Solvent**

Non-volatile solvent was selected based on the solubility study. The solubility of lafutidine in different non-volatile solvent like propylene glycol, PEG 200, PEG 400, PEG 600, glycerin, span 80, and tween 80 were determined. The results of solubility of lafutidine in various non-volatile solvent were shown in Fig. 2. On the base of saturated solubility study, lafutidine has maximum solubility in PEG-600 (48.16 mg/mL); so, PEG-600 was selected as non-volatile solvent for the formulation of liquisolid tablet.

**Selection of Carrier and Coating Material**

Screening of carrier and coating material base on liquid retention potential (\( \Phi \) value). Angle of repose determination is an important step in the development of liquisolid tablets. The relationship of angle of repose with corresponding liquid retention potential of carrier, like avicel PH 101, avicel PH 102, and lactose, are shown in Fig. 3A. From the result, it was concluded when the amount of PEG-600 increases the angle of repose increase, which results in decrease in flow property of powder. The \( \Phi \) value which corresponded to an angle of repose 33° was reported to represent the flowable liquid retention potential of powder admixture. Here, avicel PH 101 has 0.1876 highest \( \Phi \) value was found at angle of repose corresponding to the 33°. So, avicel PH 101 was selected as carrier material. The relationship of angle of repose with corresponding liquid retention potential of coating material like aerosil, aerosil 200, and cab-o-siare

---

**Fig. 1:** Characterization and drug-excipients compatibility study; A: FTIR spectra of pure lafutidine; B: FTIR spectra of formulation; C: DSC thermogram of pure lafutidine; D: DSC thermogram of lafutidine liquisolid tablet checkpoint batch

**Fig. 2:** Solubility of lafutidine in different non-volatile solvents

**Fig. 3:** A: Comparison of \( \Phi \) value of carrier materials in PEG-600; B: Comparison of \( \Phi \) value of coating materials in PEG-600
are shown in Fig. 3B. Result shown that when PEG-600 increases angle of repose increase, which results in decrease in flow property of powder. Here, aerosil-200 has 0.6755 highest Ø value was found at angle of repose corresponding to the 33°. So, aerosil-200 was selected as coating material. The angle of repose of coating material aerosil-200 has highest liquid retention potential (0.6755) compared to other coating material at 33°. So, we have selected avicel PH 101 as carrier material and aerosil-200 as coating material.

Evaluation of Preliminary Trial Batches of Lafutidine Liquisolid Tablets

To find out the effect of carrier to coating material ratio (R) and amount of non-volatile solvent (PEG-600) for that various trial batches were formulated and evaluated for pre- and post-compression characteristic parameters result are shown in Table 3. Batch T1, T2, T3, and T4 was shown acceptable characteristics of liquisolid tablets, where batch T5 had not acceptable hardness and friability. Therefore, carrier to coating material ratio was more than 20; it was difficult to formulate of liquisolid tablet. Hence, further trials were carried out using combination of carrier to coating material ratio (R) and PEG-600 in order to understand their effect, and to optimize concentration of both for desired release profile.

Evaluation of Full Factorial Batches of Lafutidine Liquisolid Tablets

Full factorial batches some evaluation are summarized in Tables 4 and 5. It was cleared that all the batches F1 to F9 showed good flow properties. Bulk density and tapped density were found to be in range 0.37 ± 0.02 to 0.5 ± 0.08, and 0.44 ± 0.05 to 0.57 ± 0.07, respectively. Values of Care's index and Hausner ratio were found according to an acceptable limit. Minimum angle of repose was found to be 21.66 ± 0.6°, and maximum was 27.35 ± 0.49°, which indicated adequate powder flow property. Variation in angle of repose could be attributed to the presence of PEG-600 in the formulations. Angle of repose was showed that when carrier to coating material ratio (R value) increase, there was increase in angle of repose. F1 had a lowest angle of repose because of low amount of PEG-600 and low amount of carrier to coating material ratio (R). Hardness of liquisolid tablets decrease as ratio of carrier to coating and amount of PEG-600 increased. Result of weight variation and friability were also according to acceptable limit. Disintegration time was found in range 1.03 ± 0.05 to 4.95 ± 0.02. When the

Table 3: Evaluation of preliminary trial batches of lafutidine liquisolid tablets

| Batch | Angle of repose (Θ) | Hardness (kg/cm²) | Friability (%) | Drug content (%) | Disintegration time (min) | % drug release at 60 min |
|-------|---------------------|-------------------|----------------|-----------------|------------------------|------------------------|
| T1    | 27.96 ± 0.36        | 4.2 ± 0.28        | 0.2 ± 0.01     | 91.3 ± 0.04     | 1.03 ± 0.05            | 55 ± 1.5               |
| T2    | 29 ± 0.53           | 4.3 ± 0.28        | 0.33 ± 0.02    | 92.2 ± 0.04     | 2.06 ± 0.11            | 64.5 ± 1.2             |
| T3    | 30.59 ± 0.56        | 4.1 ± 0.28        | 0.52 ± 0.01    | 94.7 ± 0.04     | 2.15 ± 0.05            | 74.3 ± 1.1             |
| T4    | 31.5 ± 0.27         | 3.9 ± 0.28        | 0.82 ± 0       | 98.8 ± 0.04     | 2.5 ± 0.23             | 85.5 ± 1.1             |
| T5    | 34.1 ± 0.18         | 2.5 ± 0.28        | 1.16 ± 0.05    | 98.4 ± 0.04     | 2.9 ± 0.17             | 90.8 ± 1.2             |

Table 4: Runs and measured responses of 3² factorial design batches

| Batch | Ratio of carrier to coating material = R (X₁) | Amount of PEG-600 = X₂ | Hardness (Y₃) | Angle of repose (Θ) | % cumulative drug release (% Q₅) | Disintegration time (Y₄) |
|-------|---------------------------------------------|------------------------|---------------|---------------------|----------------------------------|------------------------|
| F₁    | -1                                          | -1                     | 4.72 ± 0.1    | 21.66 ± 0.6         | 15.09 ± 0.07                     | 3.47 ± 0               |
| F₂    | 0                                           | -1                     | 4.62 ± 0.05   | 23.34 ± 1.43        | 15.84 ± 0.07                     | 3.61 ± 0.1             |
| F₃    | 1                                           | -1                     | 3.82 ± 0.1    | 24.99 ± 0.08        | 14.23 ± 0.08                     | 4.95 ± 0.02            |
| F₄    | -1                                          | 0                      | 4.98 ± 0.05   | 23.66 ± 1.59        | 24.92 ± 0.04                     | 2.33 ± 0.33            |
| F₅    | 0                                           | 0                      | 4.68 ± 0      | 24.68 ± 1.08        | 25.88 ± 0.08                     | 2.40 ± 0.02            |
| F₆    | 1                                           | 0                      | 4.14 ± 0      | 25.88 ± 1.92        | 26.36 ± 0.08                     | 2.55 ± 0               |
| F₇    | -1                                          | 1                      | 5.00 ± 0.05   | 23 ± 1.43           | 27.09 ± 0.04                     | 1.03 ± 0.05            |
| F₈    | 0                                           | 1                      | 4.54 ± 0.1    | 25.1 ± 0.41         | 23.45 ± 0.04                     | 1.16 ± 0.05            |
| F₉    | 1                                           | 1                      | 3.55 ± 0.05   | 27.35 ± 0.49        | 24.21 ± 0.04                     | 2.10 ± 0.05            |

Factors and the levels in the design

| Independent variables | Low (-1) | Medium (0) | High (1) |
|-----------------------|----------|------------|----------|
| Carrier to coating material ratio R (X₁) | 5        | 12.5       | 20       |
| Amount of PEG-600 (X₂) | 35.06    | 58.43      | 81.8     |

n = 6
The results of multiple regression analysis, it was found that all factors had statistically significant influence on all dependent variables as p < 0.05.

**Effect of Formulation Variable on Hardness (Y<sub>1</sub>)**

\[ Y_1 = 4.76 - 0.53X_1 - 0.012X_2 - 0.14X_3 - 0.25X_1^2 - 0.23X_2^2 \]

From the 3D response surface plot (Fig. 5A) and the regression coefficient values of factors, it was concluded that hardness of lafutidine liquisolid tablets decrease with increase in amount of carrier to coating material (R) and amount of PEG-600. From regression it is observed X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>1</sub>X<sub>2</sub>, and X<sub>2</sub>X<sub>3</sub> were significant model terms, which affect the on hardness. Interaction and nonlinearity was not observed. The results also indicated that the ratio of carrier to coating material was given a more significant effect on hardness as compared to PEG-600. The value of correlation coefficient (R<sup>2</sup>) was found to be 0.9306.

**Effect of Formulation Variables on Angle of Repose (Y<sub>2</sub>)**

\[ Y_2 = 24.7 + 1.65X_1 + 0.91X_2 + 0.25X_1X_2 - 0.05X_1^2 - 0.5X_2^2 \]

The results of multiple regression analysis and 3D response surface plot (Fig. 5B) showed that coefficient b<sub>1</sub> and b<sub>2</sub> bear
a positive; that indicates when the amount of carrier to coating material ratio (R) and amount of PEG-600 was increase, the angle of repose was also increase. Sign of $b_{12}$ is positive, which indicates that combine effects of $X_1$ and $X_2$ is positive on the angle of repose variable. The results also indicated that the ratio of carrier to coating material was given a more significant effect on angle of repose as compared to PEG-600. The value of correlation coefficient ($R^2$) was found to be 0.9517.

**Effect of Formulation Variables on % of Cumulative Drug Release at 5 Minutes ($Q_5$) ($Y_3$)**

$Y_3 = 26.44 - 0.39X_1 + 5.93X_2 - 0.6X_1X_2 - 0.29X_1^2 - 0.3X_2^2$

The results of multiple regression analysis and 3D response surface plot (Fig. 5C) showed that coefficient $b_1$ bears a negative sign and coefficient $b_2$ bear positive sign. The negative sign indicates that as the amount of carrier to coating material ratio increases, there is decrease in the % of cumulative drug release at 5 minutes ($Q_5$). The positive sign indicates that as the amount of % cumulative drug release at 5 minutes ($Q_5$). Sign of $b_{12}$ is negative, which indicates that combine effect of $X_1$ and $X_2$ is negative on the $Q_5$ variable. The value of correlation coefficient ($R^2$) was found to be 0.9414.

**Effect of Formulation Variables on Disintegration Time ($Y_4$)**

$Y_4 = 2.19 + 0.46X_1 - 1.29X_2 + 0.1X_1X_2 + 0.34X_1^2 + 0.29X_2^2$

From the 3D response surface plot (Fig. 5A) and the regression coefficient values of factors, it was concluded that when carrier to coating material ratio (R) increases, the disintegration time is also increased. The negative sign of $X_2$ coefficient indicates that as the amount of PEG-600 increase, the disintegration time was decreased. Sign of $b_{12}$ is positive, which indicate that combine effect of $X_1$ and $X_2$ is positive on the disintegration time variable. The value of correlation coefficient ($R^2$) was found to be 0.9506.

### Formulation and Evaluation of Check Point Batch

A checkpoint batch was designed according to the desirability function, as shown in Table 7. To validate the evolved mathematical, a checkpoint batch was prepared and evaluated under the same conditions as outlined for the other batches. The response data was compared with that of the required data. The results were found within acceptable limit that assure adequate composition of liquisolid tablets of lafutidine. The application of desirability function gives possibility to predict the optimum levels for the independent variables. In this study, the following constraints were arbitrarily used for the selection of an optimized batch: hardness: 3 to 5.5, angle of repose: 25 to 30, % of cumulative drug release at 5 minutes ($Q_5$) > 27.09%, and disintegration time < 1.3 minutes. Desirability value was close to one, in different criteria for the optimization of lafutidine 10 mg liquisolid tablets, as shown in Table 7. All four responses were targeted in order to get desired release profile. The partial desirability function (di) of each of the responses and the calculated geometric mean as the maximum global desirability.
function (D = 1), are presented in Fig. 6. The optimized batch results are found to be within the pharmacopoeial limits and showed highest drug release of 99.06 ± 0.08% at 60 minutes. The stability study was performed according to ICH guideline. The optimized formulation was kept at 40°C and 75% RH in order to check out the stability of the liquisolid tablet. The samples were analyzed for various evaluation parameters before and after stability study. The results showed similarity with that of earlier evaluated parameters. There is no significant difference between, before and after stability of optimized formulation. Hence, the formulation was found to be stable during accelerated stability study. The similarity factor (f2) was found to be 71.25 at accelerated condition (40°C and 75% RH).

The present investigation lafutidine 10 mg liquisolid tablet was successfully formulated. There was no drug-excipient interaction found in FTIR and DSC study. Preliminary screening of non-volatile solvents, carrier materials, and coating materials were conducted to select the suitable excipients. From the results of preliminary studies, PEG-600 was used as non-volatile solvent, avicel PH 101, and aerosil-200 were used as carrier and coating material. The carrier to coating material ratio (X1) and polyethylene glycol 600 (X2) was chosen as independent variables in 3² full factorial design, while hardness (Y1), angle of repose (Y2), % of cumulative drug release at 5 minutes Q5 (Y3), and disintegration time (Y4), were taken as dependent variables. The effect of independent variables on dependent variables was studied by analyzing response surface plot and polynomial equation. Optimization of lafutidine 10 mg liquisolid tablets was performed by desirability function. A checkpoint batch was designed according to the results of desirability value and evaluated for all the parameters. The results of comparison of predicted response and obtained response were found in good agreement. The formulation was found to be stable during accelerated stability study. Liquisolid technique was proved to be an effective method for solubility enhancement and improving dissolution profile of poorly soluble drug.

Acknowledgements
The authors thank Emcure Pharmaceutical Ltd., Mumbai, for providing lafutidine drug as a gift sample for the present investigation. They also would like to thank Smt. C. V. Gajera Pharmacy Mahila College, Amreli, for providing essential facilities to carry out the research work.

References
1. Patel UB, Modi DC, Shah DP. Liquisolid compacts: A review. International Journal of Advances in Pharmaceutics. 2017;6(7):110-113.
2. Patel BB, Shah CN. Recent research on liquisolid technology for solubility enhancement - A review. International Journal of Advance in Pharmaceutics. 2016;5(1):345-394.
3. Komala DR, Janga KY, Jukanti R. Competence of raloxifene hydrochloride loaded liquisolid compacts for improved dissolution and intestinal permeation. J Drug Deliv Sci Technol. 2015;30:232-241.
4. Pavani E, Noman S, Syed IA. Liquisolid technique based sustained release tablet of trimetazidine dihydrochloride. Drug Invention Today. 2013;5:302-310.
5. Sanka K, Poienti S, Mohd AB. Improved oral delivery of clonazepam

### Table 7: Formulation and evaluation of checkpoint batch and comparison with predicted value

| Ingredients                        | Formulation (mg) |
|------------------------------------|------------------|
| Lafutidine                         | 10               |
| Amount of PEG-600                  | 79.54            |
| Ratio of carrier to coating (R)    | 5.5              |
| Liquid load factor (Llf)            | 0.3104           |
| Avicel PH 101                      | 288.46           |
| Aerosil-200                        | 52.44            |
| Sodium starch glycolate             | 21.52            |
| Polyvinyl pyrrolidone K-30         | 21.52            |
| MG Stearate                        | 4.3              |
| Total                              | 477.78           |

| X1   | X2   | Parameters        | Predicted | Observed | Bias (%) |
|------|------|-------------------|-----------|----------|----------|
| 79.54| 5.5  | Hardness (Y1)     | 5.15      | 5        | 2.91     |
|      |      | Angle of repose (Y2) | 28.04     | 27.43    | 2.17     |
|      |      | Q5 (Y3)           | 27.54     | 26.09    | 5.26     |
|      |      | Disintegration time (Y4) | 1.97      | 1.1      | 9.09     |

Fig. 6: Desirability values of responses
through liquisolid powder compact formulations: *in vitro* and *ex vivo* characterization. Powder Technol. 2014;256:336-344.

6. Khames A. Liquisolid technique: a promising alternative to conventional coating for improvement of drug photostability in solid dosage forms. Drug Deliv. 2013;10:13351343.

7. Oza N, Sagar S. Optimization of dispersible pediatric cefuroxime axetil tablet containing ion-exchange resin as a taste masking agent using a $3^2$ full factorial design. International Journal of Applied Pharmaceuticals. 2019;11(4):325-332.

8. Darshan S, Rushabh S, Hemangi J, Patel PM. Liquisolid technique: a review. Int J Modern Pharm Research. 2013;2:24-34.

9. Vijay KN, Ramaroo T, Jayaveer K. Liquisolid compact a novel approach to enhance bioavailability of poorly water soluble drug. Int J Pharm Bio Sci. 2011;1:89-102.

10. Gandhi K, Sawant A, Nagpure S, Deshmanc S, Biyani K. Formulation, development, characterization and evaluation of liquisolid tablet containing pioglitazone HCl. Int J Pharm. 2013;3:122-130.

11. Kaur M, Bala R, Arora S. Formulation and evaluation of liquisolid compacts of amlodipine besylate. Int Res J Pharm. 2013;4(1):156-160.

12. Kanugo A, Chavan P, Potnis V. Melt evaporation method: a solid dispersion strategy to enhance solubility and dissolution of lafutidine. World J Pharm Res. 2013;2(6):22842300.

13. Ranga S, Jainmini M, Sharma S, Chauhan B, Kumar A. A review on Design of Experiments (DOE). Int J Pharm Chem Sci. 2014;3(1):216-240.

14. Wold N. Use of Experimental Design in the Pharmaceutical Industry. J Pharm Bio Ana. 1991;9(8):605-610.

15. Khalid E, Ahmed S, Mohamed F. Formulation and evaluation of rofecoxib liquisolid tablets. Int J Pharm Sci Res. 2010;3:135-142.

16. Boghra R, Patel A, Desai H, Jadhav A. Formulation and evaluation of irbesartan liquisolid tablets. Int J Pharm Sci Rev. 2011;9:32-37.

17. Babatunde A, Aml AN, Ebtessam AE, Sahar E. Liquisolid systems to improve the dissolution of furosemide. Sci Pharm. 2010;1:1-20.

18. Javadzadeh Y, Jafari B, Nokhodchi A. Liquisolid technique for dissolution rate enhancement of a high dose water insoluble drug (Carbamazepine). Int J Pharm. 2007;34:26-34.

19. Onodera S, Nishida K, Takeuchi K. Unique Profile of Lafutidine, a novel histamine H$_2$-receptor agonist mucosal protection throughout gastrointestinal tract mediated by capsaicin-sensitive afferent neurons. Drug Design Rev. 2004;1(2):133-144.

20. Parekh R, Patel P, Patel C, Patel K, Patel H. Development and validation of UV spectrophotometric method for estimation of lafutidine in bulk and pharmaceutical dosage form. Int J Drug Dev Res. 2012;4:325-329.

21. Patil S, Talele G. Gastroretentive mucoadhesive tablet of lafutidine for controlled release and enhanced bioavailability. Drug Del. 2014;22(3):1-8.

22. Cartensen J. ICH Guidelines in Drug Stability Principles and Practices, Edition 2, New York, Marcel Dekker. 1995;514-546.

**HOW TO CITE THIS ARTICLE:** Gohil T, Oza N, Vekariya H. Quality by design (QbD) approach for enhancement—the dissolution rate of lafutidine liquisolid tablets. Int. J. Pharm. Sci. Drug Res. 2020;12(3):238-246. **DOI:** 10.25004/IJPSDR.2020.120305